Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment

Area of Science:

• Regenerative Medicine
• Immunotherapy
• Scleroderma Research

Background:

• Scleroderma is a complex autoimmune disease characterized by fibrosis and immune dysregulation.
• Current treatments for scleroderma have limitations, necessitating novel therapeutic strategies.
• Cell therapy offers a promising avenue for precision treatment of scleroderma.

Purpose of the Study:

• To systematically review the research progress of mesenchymal stem cell (MSC) and chimeric antigen receptor T cell (CAR-T) therapies for scleroderma.
• To discuss the challenges and future directions for the development of these cell-based treatments.
• To explore the potential synergistic effects of different cell therapies in managing scleroderma.

Main Methods:

• Systematic review of existing literature on MSC and CAR-T cell therapies in scleroderma.
• Analysis of the mechanisms of action for MSCs (immunomodulation, anti-fibrosis, vascular regeneration) and CAR-T cells (targeted elimination of autoreactive cells).
• Evaluation of cell-free therapies derived from MSCs, such as exosomes.

Main Results:

• MSCs demonstrate potential in alleviating skin fibrosis through paracrine effects, inhibiting CCL2 production, and reducing macrophage recruitment.
• CAR-T cell therapy offers specific targeting and elimination of autoreactive immune cells, with potential for personalized treatment.
• Complementary and synergistic effects between MSCs and CAR-T cells are anticipated, enhancing therapeutic efficacy.

Conclusions:

• Cell therapy, including MSCs and CAR-T cells, represents a significant advancement in the precision treatment of scleroderma.
• Overcoming challenges requires integrating basic and clinical research, standardizing protocols, and developing personalized treatment plans.
• Combining cell therapy with existing treatments is crucial for maximizing benefits and improving patient prognosis and quality of life.